NCT04999202
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Misc Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes: Breast cancer patients are only eligible for dose escalation phase
Exclusions: Patients who have not progressed on treatment with an anti-PD1/L1 monoclonal antibody (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab); Patients with known active central nervous system (CNS metastases and/or leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04999202